Praxis Precision Medicines, Inc. (PRAX)

Acerca de Praxis Precision Medicines, Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

Al 3 de noviembre de 2026, la acción de Praxis Precision Medicines, Inc. (PRAX) subió con fuerza a $283.18, un alza de 3.35% (+$9.19) frente al cierre anterior. En la sesión, las acciones han operado entre $276.00 y $286.04. Eso ubica a PRAX cerca de la mitad de su rango de 52 semanas, de $154.45 a $392.70. Praxis Precision Medicines, Inc. opera en el sector de pharmaceutical preparations y tiene una capitalización de mercado de aproximadamente $7.98 mil millones, con cerca de 47.3 mil acciones negociadas.

Últimas noticias de PRAX

• Is Investor Day Plans Altering The Investment Case For Praxis Precision Medicines (PRAX)?Yahoo Finance· 28 oct, 9:10 a.m. ET
• Praxis Precision Medicines Announces Third Quarter 2026 Financial Results Date, Investor Day and November Conference ParticipationYahoo Finance· 27 oct, 4:01 p.m. ETCNS
• Epilepsy Market Set to Grow During the Forecast Period (2026-2036) as Novel Antiseizure Therapies Gain Momentum | DelveInsightYahoo Finance· 27 oct, 10:31 a.m. ET
• Is Praxis Precision Medicines (PRAX) Priced Too Highly On Book Value?Yahoo Finance· 18 oct, 5:12 p.m. ET
• Workday downgraded, Fox Corp. upgraded: Wall Street's top analyst callsYahoo Finance· 16 oct, 9:38 a.m. ET
• Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance· 2 oct, 4:01 p.m. ETCNS
• Praxis (PRAX) Q2 2026 Earnings Call Transcriptfool.com· 13 ago, 12:29 p.m. ET
• 4 Biotech Stocks With Major Second-Half Pipeline Catalysts This YearYahoo Finance· 11 ago, 10:01 a.m. ET

Fuente: Yahoo Finance RSS · Actualizado el 3 de noviembre de 2026

¿Quieres titulares, alertas e investigación con IA de PRAX en un solo lugar? Crea una cuenta gratis →

• $PRAX PART #1 FYI - Here’s a short summary of the targeted anti-epileptic/anti-seizure therapeutics mentioned below by Merlin Trader. If you have technical questions or want additional information, please look up the specific study at www.clinicaltrials.gov. For analyst share …

  @Trainguy1· 3 nov, 9:11 a.m. ET

• $PRAX PART #2 • Praxis Relutrigine: Currently this drug is under FDA review for possible marketing approval to treat SCN2A/SCN8A developmental and epileptic encephalopathies (DEEs). The drug is also currently undergoing a phase 3 clinical trial for treating a broad set of DEEs…

  @Trainguy1· 3 nov, 9:10 a.m. ET

• $PRAX PART #3 • Rapport RAP-219: Currently this oral drug is undergoing phase 3 clinical trials for treating adults with focal seizures (FOCUS 1 & FOCUS 2 studies). If the quantity of seizures per month decreases, then RAP-219 could be approved. • Stoke Zorevunersen: This …

  @Trainguy1· 3 nov, 9:09 a.m. ET

• $PRAX $RAPP $STOK $XENE Epilepsy beyond seizure counts: new sector report Praxis (relutrigine in SCN2A/SCN8A DEEs), Rapport (RAP-219 in focal seizures), Stoke (zorevunersen in Dravet syndrome) and Xenon (azetukalner application). The report separates seizure reduction from dis…

  @Merlintrader· 1 nov, 4:06 a.m. ET

• $PRAX closed the week at $285.93 (+13.0% w/w, -0.9% Friday), below the 50-day SMA ($301.29) and below the 200-day ($314.83). RSI14 55.0. Support $236.79, resistance $299.12 (20-day range, top). Broad market sell-off on Friday. New hub updated: https://www.merlintrader.com/prax/

  @Merlintrader· 31 oct, 5:39 p.m. ET

Fuente: Stocktwits. Las publicaciones de usuarios son opiniones, no hechos verificados. Ver lo que es tendencia →